Patents Assigned to University of Maryland, Baltimore
  • Patent number: 11513061
    Abstract: A device for monitoring at least one parameter of a fluid specimen obtained from a patient. The device has a fluid conduit holder comprising a clamp configured to position a fluid conduit, which holds the fluid specimen obtained from the patient, in a position for optical analysis, and an optical analyzer having a light source and a light detector. The optical analyzer is configured to expose the fluid specimen contained within the fluid conduit to an illuminant and measure light received at the detector. The device has an optical alignment mechanism mechanically coupling the light source, the clamp, and the light detector together, and configured to align at least the light detector with the fluid conduit at the position for optical analysis.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: November 29, 2022
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Michael T. McCurdy, Rajagopal Srinivasan
  • Patent number: 11510908
    Abstract: Provided herein are protein translation inhibitors and pharmaceutical compositions thereof that bind to an RNA Recognition motif in heterogeneous ribonucleoprotein A18 to inhibit binding to mRNA transcripts thereby inhibiting protein synthesis. Also provided is a method for treating a cancer by administering a pharmaceutically acceptable amounts of at least one of the protein translation inhibitors.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: November 29, 2022
    Assignee: University of Maryland, Baltimore
    Inventors: France Carrier, Alexander D. MacKerell, David J. Weber, Wenbo Yu
  • Patent number: 11504390
    Abstract: The present disclosure provides methods of treating subjects having increased lipid levels, methods of identifying subjects having an increased risk of developing an increased lipid level, methods of detecting human Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) variant nucleic acid molecules and variant polypeptides, and SREBF1 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: November 22, 2022
    Assignees: Regeneron Pharmaceuticals, Inc., University of Maryland, Baltimore
    Inventors: Alan Shuldiner, Nehal Gosalia, Cristopher Van Hout, Da-Wei Gong, James A. Perry
  • Patent number: 11497872
    Abstract: The present invention provides an improved percutaneous dilation tracheostomy device. The device is configured to include all of the required components to perform a percutaneous tracheotomy. The device includes a retractable needle and an extendable j-wire rather than having separate components as in typical percutaneous tracheostomy devices. The device includes a dilator section to expand the diameter of a patient's stoma. The device is further configured to allow an operator to perform a bubble test to alert the user that the tube is in the trachea. In addition, the device is generally more compact than typical emergency tracheostomy devices.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: November 15, 2022
    Assignees: University of Maryland, Baltimore, University of Maryland, College Park
    Inventors: Joseph Rabin, Conor Bloomer, Paige Chan, Scott Kivitz, Peter Chen, Torrance Wang
  • Patent number: 11493428
    Abstract: Described herein are microfluidic devices and methods that can greatly improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 8, 2022
    Assignees: GPB SCIENTIFIC, INC., UNIVERSITY OF MARYLAND, BALTIMORE, THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Michael Grisham, Curt I Civin, James C. Sturm, Robert H. Austin, Joseph D'Silva, Yu Chen
  • Patent number: 11485762
    Abstract: The present disclosure relates to compositions and methods for inhibiting L-plastin activity for inhibiting bone resorption activity of osteoclasts. In certain instances, the compositions and methods are used to treat or prevent a disease or disorder associated with bone resorption. In one aspect, the compositions and methods relate to peptide inhibitors comprising an N-terminal fragment of L-plastin.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: November 1, 2022
    Assignee: University of Maryland, Baltimore
    Inventor: Meenakshi Chellaiah
  • Patent number: 11486802
    Abstract: Described herein are devices and methods for high throughput purification of particles. In some cases, methods and devices described herein can be used to remove erythrocytes and purify leukocytes and raise the quality of umbilical cord blood and other transplant grafts, thereby significantly improving patient outcomes.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: November 1, 2022
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Joseph D'Silva, Robert H. Austin, Curt Civin, James C. Sturm
  • Patent number: 11483294
    Abstract: The invention described herein is directed to methods and systems for protecting network trace data. Network traces are used for network management, packet classification, traffic engineering, tracking user behavior, identifying user behavior, analyzing network hierarchy, maintaining network security, and classifying packet flows. In some embodiments, network trace data is protected by subjecting network trace data to data anonymization using an anonymization algorithm that simultaneously provides sufficient privacy to accommodate the organization need of the network trace data owner, provides acceptable data utility to accommodate management and/or network investigative needs, and provides efficient data analysis, at the same time.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: October 25, 2022
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventors: George Karabatis, Zhiyuan Chen, Ahmed Aleroud, Fan Yang
  • Patent number: 11478665
    Abstract: Techniques for particle beam therapy include receiving a target region inside a subject for particle therapy, a minimum dose inside the target region, and a maximum dose inside the subject but outside target region. Multiple beam axis angles are determined, each involving a gantry angle and a couch position. Multiple spots within the target region are determined. For each beam axis angle a pristine particle scan beam (not coaxial with any other particle scan beam) is determined such that a Bragg Peak is directed to a spot, and repeated until every spot is subjected to a Bragg Peak or an intersection of two or more such pristine scan beams. Output data indicating the pristine beamlets is stored for operation of a particle beam therapy apparatus.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: October 25, 2022
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: James William Snider, III, William F. Regine, Mingyao Zhu, Katja Langen
  • Patent number: 11474097
    Abstract: A cell-based quantitative high-throughput screening assay to monitor the formation of PFK1-mEGFP clusters by the action of small molecules to identify small molecules that promote intracellular PFK1 clustering in a cell cycle-dependent manner and may be used to treat cancer.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: October 18, 2022
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY, NATIONAL INSTITUTES OF HEALTH
    Inventors: Songon An, Danielle L. Schmitt, James Inglese, Patricia Dranchak
  • Patent number: 11471520
    Abstract: The invention relates to a multivalent Shigella/Enterotoxigenic Escherichia coli vaccine for use in prophylaxis and treatment of diarrheal disease. The Shigella-ETEC vaccine provides increased coverage of a broader range of ETEC and Shigella isolates than prior vaccines, and includes CS14 antigens and serotypes (S. flexneri 7a, or S. flexneri 1b).
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: October 18, 2022
    Assignee: University Of Maryland, Baltimore
    Inventors: Eileen M. Barry, Myron M. Levine
  • Patent number: 11464813
    Abstract: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: October 11, 2022
    Assignee: University of Maryland, Baltimore
    Inventors: Jacques Ravel, Michael France, Lindsay Rutt, Bing Ma
  • Patent number: 11466075
    Abstract: Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 11, 2022
    Assignee: University of Maryland, Baltimore
    Inventors: Hanping Feng, James Eugene Galen, Kevin Chen, Yixuan Zhu
  • Patent number: 11459313
    Abstract: The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: October 4, 2022
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, MCDANIEL COLLEGE
    Inventors: Ashkan Emadi, Rena G. Lapidus, Brandon A. Carter-Cooper, Steven Fletcher, Dana Ferraris, Edward A. Sausville
  • Patent number: 11459320
    Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: October 4, 2022
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Scott Thompson, Adam Van Dyke, Craig Thomas, Patrick Morris
  • Patent number: 11440946
    Abstract: A universal antibody-mediated biosensor is provided that comprise a biosensor cell line stably expressing a novel chimeric fusion protein that can be used to detect target agents in a sample. The fusion protein has an extracellular antibody-binding domain that binds antibodies without regard to their binding specificity and a signaling domain that induces cellular activation upon antigen binding. Because the fusion protein binds to the Fc region of any antibody, it can serve as a universal pathway between extracellular signaling and intracellular activation. The biosensor can be used to detect the presence of selected antigens in a sample.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: September 13, 2022
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Dan Schulze, Scott E. Strome
  • Patent number: 11435343
    Abstract: The present invention relates to surface plasmon-coupled bioluminescence, wherein bioluminescent emission from a bioluminescent chemical reaction couples to surface plasmons in metalized particles thereby enhancing the signal. Importantly, these plasmonic emissions emitted from metallic particles generated without an external excitation source but instead from induced electronically excited states caused by the bioluminescent chemical reaction.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: September 6, 2022
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventor: Chris D. Geddes
  • Patent number: 11433168
    Abstract: The device of the present invention includes a dual chamber gas exchanger that is configured for increased flexibility and scalability for many clinical applications. The dual chamber oxygenator can be configured and used in various applications, such as in a heart-lung machine for cardiopulmonary support during cardiothoracic surgery, in an extracorporeal membrane oxygenation (ECMO) circuitry, as a respiratory assist device for patients with lung failure, and the like. The dual chamber gas exchanger features two sweep gas flow paths and two gas exchange membrane bundles enclosed in a housing structure with various blood flow distribution and gas distribution mechanisms. The gas exchanger includes an outer housing, an intermediate housing, two gas exchange fiber bundles, a blood inlet, a blood outlet, two gas inlets, two gas outlets, two gas distribution chambers and an optional heat exchanger.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 6, 2022
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, BREETHE, INC.
    Inventors: Zhongjun Wu, Bartley P. Griffith, Jiafeng Zhang, Steven J. Orwig
  • Publication number: 20220273608
    Abstract: Provided herein are methods for treating a bone-related disorder in a subject. At least one of a microtubule altering drug, for example, a microtubule disrupting drug or a microtubule stabilizing drug, a TRPV4 agonist or a NOX2 activator is administered to the subject. Also provided are related methods for treating a bone-related disorder in the subject by further administering at least one of an anti-sclerostin agent, a parathyroid hormone agonist, a bisphosphonate, an estrogen mimic, or a selective estrogen receptor modulator with the at least one of a microtubule altering drug, a TRPV4 agonist or a NOX2 activator.
    Type: Application
    Filed: May 16, 2022
    Publication date: September 1, 2022
    Applicant: University of Maryland, Baltimore
    Inventors: Joseph Stains, Christopher Ward, James Lyons
  • Publication number: 20220273680
    Abstract: Provided herein are methods for preventing or treating a psychological disorder. A serotonin agonist or an agonist of serotonin receptors is administered separately, sequentially or simultaneously in combination with a serotonin receptor 2A antagonist.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 1, 2022
    Applicant: University of Maryland, Baltimore
    Inventor: Thompson Scott